Cargando…
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
Oncolytic viruses (OVs) target and destroy cancer cells while sparing their normal counterparts. These viruses have been evaluated in numerous studies at both pre-clinical and clinical levels and the recent Food and Drug Administration (FDA) approval of an oncolytic herpesvirus-based treatment raise...
Autores principales: | Marchini, Antonio, Scott, Eleanor M., Rommelaere, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728569/ https://www.ncbi.nlm.nih.gov/pubmed/26751469 http://dx.doi.org/10.3390/v8010009 |
Ejemplares similares
-
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
por: Nakashima, Hiroshi, et al.
Publicado: (2015) -
Emerging role of Natural killer cells in oncolytic virotherapy
por: Bhat, Rauf, et al.
Publicado: (2015) -
Overcoming the limitations of locally administered oncolytic virotherapy
por: Hong, JinWoo, et al.
Publicado: (2019) -
Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)